Improving malaria treatment during pregnancy


Due to a shortage of safety data on pregnant women for most of the currently recommended malaria treatments, there are limited treatment options for this vulnerable population, particularly in the first trimester.


As a recognized leader in antimalarial drug discovery, development and delivery, MMV aims to provide informed therapeutic choices for malaria treatment and protection across all genders and age categories, including pregnant and lactating women. For more information download MMV's MiMBa strategy